MedTrace Logo

Study With QR-504a to Evaluate Safety, Tolerability & Corneal Endothelium Molecular Biomarker(s) in Subjects With FECD3

NCT05052554 · Status: WITHDRAWN · Phase: PHASE1 · Type: INTERVENTIONAL

Last updated 2022-05-11

No results posted yet for this study

Summary

PQ-504a-001 (Fuchs Focus) is an open-label, single-dose, exploratory study to evaluate safety, tolerability, and corneal endothelium molecular biomarker(s) in subjects with Fuchs Endothelial Corneal Dystrophy with Trinucleotide Repeat Expansion in the TCF4 gene (FECD3).

Conditions

  • Fuchs Endothelial Corneal Dystrophy
  • FECD3
  • Corneal Diseases
  • LRS
  • Descemet's Membrane Disorder

Interventions

DRUG

QR-504a

Intravitreal (IVT) injection

Sponsors & Collaborators

  • ProQR Therapeutics

    lead INDUSTRY

Principal Investigators

  • ProQR Medical Monitor · ProQR Therapeutics

Study Design

Allocation
NON_RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2021-08-10
Primary Completion
2022-04-12
Completion
2022-04-12

Countries

  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05052554 on ClinicalTrials.gov